Schwartz/Reisman Emergency Medicine Institute

Rapid Sepsis Assay

Evaluation of Qvella Rapid Molecular Assay for the Detection of Bacterial and Fungal Pathogens in Blood

Over 30,000 Canadians are hospitalized each year and more than 30% patients will die because of sepsis. One key element of effective treatment is rapid identification of bloodstream pathogens and susceptibility testing via blood cultures. Currently, blood culture results take approximately three to five days to be completed. This is due to reliance on pathogen growth in a blood culture medium prior to species identification.

Development of a new technology by Qvella, an Ontario based molecular diagnostics company, allows for pathogen identification from whole blood sampling without the need for culturing. As a result, blood culture results can be available within hours as compared to days with traditional microbiology testing.

SREMI investigators have partnered with the scientists at Qvella and colleagues in microbiology to study this new technology for emergency department patients with suspected sepsis. The objective of this prospective observational study is to compare blood culture results obtained with novel Qvella technology to conventional practice results for patient samples collected in the emergency department. It is our hope that rapid identification of microorganisms will allow physicians to expedite and tailor antimicrobial therapy for patients with suspected sepsis, resulting in improved clinical outcomes and a reduction in the use of unnecessary antibiotics.